272 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
Rank Status Study
1 Recruiting National Marrow Donor Program Long-Term Donor Follow-Up
Condition: Hematologic Neoplasms
Intervention:
2 Unknown  Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency
Condition: Growth Hormone Deficiency
Intervention: Drug: Somatropin
3 Recruiting Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Condition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: Drug: UX007 (triheptanoin);   Drug: Placebo Oil
4 Enrolling by invitation Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Condition: Catecholaminergic Polymorphic Ventricular Tachycardia
Intervention: Drug: flecainide
5 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
6 Recruiting Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide/LXS Oral Powder;   Drug: Ketoconazole;   Drug: Vincristine
7 Available Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide Lym-X-Sorb Oral Powder;   Drug: Ketoconazole
8 Recruiting Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Conditions: Vaso-occlusive Crisis;   Sickle Cell Disease
Interventions: Drug: MST-188;   Drug: Saline
9 Unknown  Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Conditions: Septic Shock;   Thrombocytopenia;   Multiple Organ Failure
Intervention:
10 Completed
Has Results
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Conditions: Sickle Cell Disease;   Iron Overload;   Hemolytic Anemia
Interventions: Drug: Deferasirox (ICL670);   Drug: Deferoxamine (DFO)
11 Completed
Has Results
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Condition: Patent Ductus Arteriosus (PDA)
Interventions: Device: Device closure with AMPLATZER Duct Occluder;   Other: Objective Performance Criteria
12 Active, not recruiting Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   NK Cell Lymphoblastic Leukemia
Interventions: Biological: Single Cord Blood Unit Transplantation;   Biological: Double Cord Blood Unit Transplantation
13 Recruiting An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
Condition: Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Intervention: Drug: Triheptanoin
14 Active, not recruiting Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
15 Active, not recruiting Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: diffusion tensor imaging;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Active, not recruiting Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Conditions: Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Spinal Cord Neoplasm;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat;   Biological: bevacizumab;   Drug: temozolomide
17 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
Conditions: Childhood Hepatoblastoma;   Stage I Childhood Liver Cancer;   Stage II Childhood Liver Cancer;   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: fluorouracil;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Procedure: liver transplantation;   Other: laboratory biomarker analysis
18 Recruiting Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Conditions: Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
19 Active, not recruiting Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Conditions: Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Gliosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
20 Active, not recruiting Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Conditions: Childhood Cerebral Astrocytoma/Malignant Glioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma
Interventions: Drug: sunitinib malate;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years